STOCK TITAN

Maplight Therapeutics (MPLT) holder files to sell 48,158 shares via Jefferies

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Maplight Therapeutics, Inc. has a planned sale of 48,158 common shares of its stock through Jefferies LLC, with an indicated sale date of July 15, 2026 on NASDAQ. The shares have an aggregate market value of $1,825,669.78, while 42,620,000 shares are outstanding. The seller, Erin Pennock Foff, acquired Maplight shares via restricted stock unit grants on several dates and has already sold multiple blocks of shares between April 15 and May 7, 2026, including 24,052 shares on May 6, 2026 for $691,814.17.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 48,158 shares Number of Maplight Therapeutics common shares planned for sale
Aggregate market value $1,825,669.78 Aggregate market value of the 48,158 shares to be sold
Shares outstanding 42,620,000 shares Maplight Therapeutics common shares outstanding
Indicated sale date 07/15/2026 Indicated date for the planned share sale
Recent sale on May 6, 2026 24,052 shares for $691,814.17 One of several recent sales by Erin Pennock Foff
RSU grant on July 18, 2025 60,346 units Restricted stock unit grant in Maplight Therapeutics common stock
Form 144 regulatory
"144: Securities Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
restricted stock unit financial
"Restricted Stock Unit Grant | Maplight Therapeutics, Inc."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
aggregate market value financial
"Common | Jefferies LLC ... | 48158 | 1825669.78 | 42620000"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Securities To Be Sold regulatory
"144: Securities To Be Sold"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What share sale is disclosed for Maplight Therapeutics (MPLT) in this Form 144?

The filing shows a planned sale of 48,158 common shares of Maplight Therapeutics through Jefferies LLC. The aggregate market value of these shares is $1,825,669.78, with trading indicated on NASDAQ and an expected sale date of July 15, 2026.

How many Maplight Therapeutics (MPLT) shares are outstanding in this filing?

The Form 144 lists 42,620,000 shares of Maplight Therapeutics outstanding. This figure provides context for the planned sale of 48,158 shares, helping investors gauge the relative size of the transaction versus the company’s total common shares.

Who is the selling shareholder in the Maplight Therapeutics (MPLT) Form 144?

The selling holder is listed as Erin Pennock Foff, with an address at 800 Chesapeake Drive, Redwood City, CA 94063. The filing details both the planned sale of 48,158 shares and several prior sales in April and May 2026.

What recent Maplight Therapeutics (MPLT) share sales has Erin Pennock Foff made?

Recent sales include 24,052 shares on May 6, 2026 for $691,814.17, 15,652 shares on May 4, 2026 for $437,576.39, and additional smaller blocks between April 15 and May 7, 2026, each with disclosed proceeds.

How were the Maplight Therapeutics (MPLT) shares being sold acquired?

The shares were acquired through restricted stock unit grants in Maplight Therapeutics, Inc. Grants include 60,346 units dated July 18, 2025 and smaller grants on July 30, 2023, November 9, 2023, and May 2, 2024, all referencing Maplight common stock.

Which broker is handling the planned Maplight Therapeutics (MPLT) share sale?

The broker listed is Jefferies LLC, located at 520 Madison Avenue, 4th Floor, New York, NY 10022. Jefferies is identified in connection with the planned sale of 48,158 Maplight Therapeutics common shares on NASDAQ.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature